FDA's "Substantial Interest" In Reviewing Off-Label Uses Noted By Judge
This article was originally published in The Gray Sheet
Executive Summary
FDA should have a "substantial interest" in adding off-label uses of previously approved medical devices and drugs to the labeling of those products, according to a decision handed down in Washington, D.C. federal court July 30.